Hepatic stellate cell contractility (HSC contractility)

Hepatic stellate cell contractility refers to the ability of hepatic stellate cells (HSCs) to generate mechanical force, primarily as part of the liver's response to injury. In quiescent (resting) HSCs, contractility is minimal, but upon activation—for example, during chronic liver injury—HSCs transition to a myofibroblast-like, contractile phenotype, expressing α-smooth muscle actin and developing a contractile apparatus similar to smooth muscle cells[1][2]. The contractility of activated HSCs plays a key role in liver pathophysiology by modulating sinusoidal blood flow (affecting intrahepatic vascular resistance and portal hypertension), participating in extracellular matrix remodeling during scar formation, and contributing to the mechanical properties of fibrotic liver tissue[1][2]. Contractility is regulated by both Ca²⁺-dependent and Ca²⁺-independent pathways, with significant evidence for the dominant role of rho-associated kinase (ROCK) signaling in activating myosin II, the molecular motor driving contraction[1][2]. Endothelin-1 is a potent pro-contractile agonist, while nitric oxide is a key relaxant, balancing local vascular tone[1][2]. HSC contractility is not a single protein or receptor, but rather a complex functional state involving multiple signaling pathways and molecular effectors. Although not a traditional "drug target" (like a single receptor or enzyme), modulation of HSC contractility is considered a therapeutic strategy for hepatic fibrosis and portal hypertension, with experimental approaches focusing on inhibiting rho/ROCK, endothelin, or calcium signaling, or enhancing nitric oxide signaling[1][2].

Other names

Liver stellate cell contractile phenotypeHepatic stellate cell myofibroblast contractilityStellate cell contractionHSC contractionPerisinusoidal cell contractility

- RhoA/Rho-associated kinase (ROCK) pathway inhibition to reduce stellate cell contraction[1]. - Inhibition of myosin regulatory light chain phosphorylation, which is required for contraction[1]. - Modulation of endothelin-1 receptor signaling, as it promotes contraction, and nitric oxide, which counteracts it[1][2]. - Calcium channel blockers or inhibitors of Ca²⁺-dependent pathways may also attenuate contractility[2].